Possibilities of pharmacologic correction of cognitive disorders in conditions of experimental equivalent of multiple sclerosis.
DOI:
https://doi.org/10.26641/2307-0404.2015.2.45638Keywords:
multiple sclerosis, experimental allergic encephalomyelitis, cognitive disorders, neuroprotectionAbstract
A comparative analysis of the impact of citicoline, α-lipoic acid, nicergoline, donepezil and colloidal solution of nano-silver (CSNS) on the processes of learning and consolidation of memorable track in the test of the conditional reaction of passive avoidance (CRPA) in conditions of experimental allergic encephalomyelitis (EAE) was conducted. Testing of passive defensive skill was performed on days 12 and 20 after the induction of EAE. To assess the impact of drugs on the inputted information processes the investigated substances were administered intragastrically (CSNS - intraperitoneally) once daily in the definite dose from the second to the day 10 after the induction of EAE (latent phase of the disease), and assessing processes of conditional skill preserving, further administration of drugs by the day 20 of the experiment (average duration of EAE) was used. A positive effect of citicoline, α-lipoic acid, nicergoline and donepezil on the input information processes and the ability to prevent accelerated extinction of acquired contingent skill in the conditions of experimental pathology was established. Drugs statistically significantly increased duration of the latent period of CRPA in comparison with a group of active control by 49%, 43%, 39% and 34%, respectively. Here with preparations were characterized by a high coefficient of antiamnesic activity, by the end of the experiment it was recorded at the level of 95% (citicoline), 81% (α-lipoic acid), 76% (nicergoline) and 53% (donepezil). It is shown that the ability to prevent development of cognitive impairment in conditions of experimental equivalent of multiple sclerosis decreases in the number of citicoline (500 mg/kg) > α-lipoic acid (50 mg/kg) ≈ nicergoline (10 mg/kg) > donepezil (10 mg/kg).References
Alekseeva TG, Bojko AN, Gusev EI. [Range of neuropsychological changes in multiple sclerosis]. The Korsakov Journal of Neurology and Psychiatry. 2000;11:15-20. Russian. 2. Alifirova VM, Orlova YuYu., Musina NF. [Cog¬nitive disturbances in patients with multiple sclerosis]. Bulletin of Siberian medicine. 2008;3:62-7. Russian. 3. Gusev EI, Zavalishin IA, Boyko AN. [Multiple scle¬rosis and other demyelinating diseases]. M: Miklosh, 2004:540. Russian. 4. Damulin IV. [The use of donepezil in Alzheimer's disease and vascular dementia]. The Korsakov Journal of Neurology and Psychiatry. 2013;7:71-75. Russian. Rus¬sian. 5. Inozemtsev AN, Belnik AP, Ostrovskaya RU. [The study of conditioned reflex of passive avoidance in a modified three-room installation]. Experimental and clinical pharmacology. 2007;70(2):67-69. Russian. 6. Bembeeva RTs, Mikadze YuV, Petruhin AS. [Cog¬nitive impairment in multiple sclerosis]. The Kor¬sakov Journal of Neurology and Psychiatry. 2006;106(12):11-19. Russian. 7. Alekseeva TG, Enikolopova EV, Sadalskaya EV. [An integrated approach to the assessment of cognitive and emotional-personal spheres in patients with multiple sclerosis]. The Korsakov Journal of Neurology and Psychiatry. 2002;20-26. Russian. 8. Mamchur VI, Dronov SN, Zhilyuk VI. [Clinical potential of nicergoline: look of a pharmacist]. NEURONEWS (psychoneurology and neuropsychiatry). 2011;3:37-40. Russian. 9. Program statistical analysis [Electronic resource]: access www.analystsoft.com/ru/ 10. Radionova KS, Belnik AP, Ostrovskaya RU. [Original nootropic drug "Noopept" eliminates the deficit in memory caused by the blockade of M - and N-cholinergic receptors in rats]. Bulletin of experimental biology and medicine. 2008;146(1):65-68. Russian. 11. Manuhina EB, Pshennikova MG, Goryacheva AV. [Role of nitric oxide in the prevention of cognitive disorders in neurodegenerative the brain-injured rats]. Bulletin of experimental biology and medicine. 2008;146(10):371-5. Russian. 12. Ethics of a physician and human rights: the re¬gulation of the use of animals in biomedical research. Clinical and Experimental physiology and biochemistry. 2003;2(22):108-9. Ukrainian. 13. Baker D, Hankey DJ. Gene therapy in auto¬immune, demyelinating disease of the central nervous system. Gene Ther. 2003;10(10):844–53. 14. Mir C, Clotet J, Aledo R, [et al.]. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Mol Neurosci. 2003;20(1):53–60. 15. Degano AL, Roth GA. Passive transfer of experi¬mental autoimmune encephalomyelitis in Wistar rats: dis¬sociation of clinical symptoms and biochemical altera¬tions. J Neurosci Res. 2000;59(2):283–90. 16. Kesselring J, Klement U. Cognitive and affective disturbances in multiple sclerosis. J Neurol. 2001;248:180–3.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
